PDF(Pubmed)
Abstract：
UNASSIGNED: The medication regimen for critically ill patients is complex and dynamic, leading to a high incidence of drug-related problems. This study aimed to assess the effectiveness and economic efficiency of pharmaceutical care for these patients.
UNASSIGNED: In this prospective cohort study conducted in a tertiary hospital, adult patients were assigned either to a clinical pharmaceutical care group or a control group based on existing clinical grouping rules. Health outcomes and economic indicators were collected, followed by a cost-effectiveness analysis.
UNASSIGNED: The acceptance rate for clinical pharmacist interventions was 89.31%. The pharmaceutical care group exhibited significant reductions in the rate of medication errors (40.65% vs. 61.69%, P < 0.001) and adverse drug events (44.52% vs. 56.45%, P = 0.020). The usage rates for special-grade antibiotics (85.16% vs. 91.13%, P = 0.009) and proton pump inhibitors (77.42% vs. 88.71%, P = 0.002) were also lower in the pharmaceutical care group. Secondary outcomes did not show significant differences in total hospital stay (21 days vs. 22 days, P = 0.092). However, ICU stay was significantly shorter (9 days vs. 11 days, P = 0.003) in the pharmaceutical care group. Cost-effectiveness analysis demonstrated that each 1% reduction in adverse drug events associated with ICU pharmaceutical care saved $226.75 in ICU hospitalization costs and $203.42 in total ICU drug costs. A 1% reduction in the medication error rate saved $128.57 in ICU hospitalization costs and $115.34 in total ICU drug costs.
UNASSIGNED: Pharmaceutical care significantly reduces adverse drug events and medication errors, promotes rational use of medications, decreases the length of ICU stay, and lowers treatment costs in critically ill patients, establishing a definitive advantage in terms of cost-effectiveness.
UNASSIGNED: In this prospective cohort study conducted in a tertiary hospital, adult patients were assigned either to a clinical pharmaceutical care group or a control group based on existing clinical grouping rules. Health outcomes and economic indicators were collected, followed by a cost-effectiveness analysis.
UNASSIGNED: The acceptance rate for clinical pharmacist interventions was 89.31%. The pharmaceutical care group exhibited significant reductions in the rate of medication errors (40.65% vs. 61.69%, P < 0.001) and adverse drug events (44.52% vs. 56.45%, P = 0.020). The usage rates for special-grade antibiotics (85.16% vs. 91.13%, P = 0.009) and proton pump inhibitors (77.42% vs. 88.71%, P = 0.002) were also lower in the pharmaceutical care group. Secondary outcomes did not show significant differences in total hospital stay (21 days vs. 22 days, P = 0.092). However, ICU stay was significantly shorter (9 days vs. 11 days, P = 0.003) in the pharmaceutical care group. Cost-effectiveness analysis demonstrated that each 1% reduction in adverse drug events associated with ICU pharmaceutical care saved $226.75 in ICU hospitalization costs and $203.42 in total ICU drug costs. A 1% reduction in the medication error rate saved $128.57 in ICU hospitalization costs and $115.34 in total ICU drug costs.
UNASSIGNED: Pharmaceutical care significantly reduces adverse drug events and medication errors, promotes rational use of medications, decreases the length of ICU stay, and lowers treatment costs in critically ill patients, establishing a definitive advantage in terms of cost-effectiveness.
摘要：
■危重病人的用药方案复杂而动态，导致毒品相关问题的高发生率。这项研究旨在评估这些患者的药学服务的有效性和经济效率。
■在这项在三级医院进行的前瞻性队列研究中，根据现有的临床分组规则,将成年患者分为临床药学服务组或对照组.收集健康结果和经济指标，其次是成本效益分析。
■临床药师干预的接受率为89.31%。药物护理组显着降低了用药错误率（40.65％vs.61.69%,P<0.001）和药物不良事件（44.52%vs.56.45%，P=0.020)。特殊等级抗生素的使用率(85.16%vs.91.13%，P=0.009）和质子泵抑制剂（77.42%vs.88.71%,P=0.002）在药物护理组中也较低。次要结局在总住院时间上没有显着差异（21天与22天,P=0.092)。然而,ICU住院时间明显缩短（9天vs.11天,药物护理组的P=0.003）。成本-效果分析表明，与ICU药物护理相关的不良药物事件每减少1％，可节省ICU住院费用226.75美元，ICU药物总费用203.42美元。药物错误率降低1％，可节省ICU住院费用128.57美元，ICU总药费115.34美元。
■药学监护显著减少药物不良事件和用药错误，促进合理使用药物，缩短ICU住院时间,降低危重病人的治疗费用，在成本效益方面建立明确的优势。
■在这项在三级医院进行的前瞻性队列研究中，根据现有的临床分组规则,将成年患者分为临床药学服务组或对照组.收集健康结果和经济指标，其次是成本效益分析。
■临床药师干预的接受率为89.31%。药物护理组显着降低了用药错误率（40.65％vs.61.69%,P<0.001）和药物不良事件（44.52%vs.56.45%，P=0.020)。特殊等级抗生素的使用率(85.16%vs.91.13%，P=0.009）和质子泵抑制剂（77.42%vs.88.71%,P=0.002）在药物护理组中也较低。次要结局在总住院时间上没有显着差异（21天与22天,P=0.092)。然而,ICU住院时间明显缩短（9天vs.11天,药物护理组的P=0.003）。成本-效果分析表明，与ICU药物护理相关的不良药物事件每减少1％，可节省ICU住院费用226.75美元，ICU药物总费用203.42美元。药物错误率降低1％，可节省ICU住院费用128.57美元，ICU总药费115.34美元。
■药学监护显著减少药物不良事件和用药错误，促进合理使用药物，缩短ICU住院时间,降低危重病人的治疗费用，在成本效益方面建立明确的优势。
